Mersana Therapeutics, Inc.

Mersana Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to pioneering novel antibody-drug conjugates (ADCs) for cancer patients with pressing unmet medical needs. Their flagship product candidate, XMT-1592, a Dolasynthen ADC engineered to target NaPi2b-expressing tumor cells, is presently undergoing Phase I clinical evaluation for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company's development pipeline also includes XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate, and XMT-2056, an Immunosynthen development candidate. Additionally, Mersana maintains strategic research and development collaborations with Merck KGaA and Asana BioSciences, LLC for the creation of ADC product candidates, leveraging its Fleximer technology. Incorporated in 2001, the company initially operated as Nanopharma Corp. before rebranding as Mersana Therapeutics, Inc. in November 2005, and is headquartered in Cambridge, Massachusetts.